Pfizer: Product portfolio and domestic growth in focus

PFIZER Pfizer: Product portfolio and domestic growth in focus Pfizer Limited (NSE: PFIZER) operates in India's pharmaceutical market, with a portfolio spanning therapies across multiple healthcare segments. Its established brands and distribution network provide a foundation for business stability. **Why it matters:** Demand for specialised medicines and branded formulations can support growth. However, product concentration, pricing regulations, competition from generic alternatives and changes in the product portfolio can influence revenue and margins. **My view:** Pfizer's investment outlook depends on sustaining its established brands while expanding its product portfolio. Consistent product launches, market share gains and disciplined cost management will be important for long-term performance. **What to watch:** Domestic formulation growth, key brand performance, new product launches, regulatory developments, operating margins and dividend sustainability. **Stance:** An established pharmaceutical franchise can offer business stability, but sustainable earnings growth and valuation remain important considerations. Disclosure: I am a SEBI Registered Research Analyst. This content is for educational purposes and is not a recommendation to buy or sell any security.